Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus blinatumomab in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
2024-517959-12-00Phase 2Completed
- Sponsor
- Goethe University Frankfurt
- Start
- Apr 2024
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Goethe University Frankfurt. Primary endpoints: Maximum tolerated dose and Molecular complete remission rate. Started Apr 2024; status: completed.
02
Drugs
venetoclaxblinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2024-517959-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517959-12-00.